Sickle-cell diseases are treated with annexin proteins that are modified to increase their half-life in the circulation.

 
Web www.patentalert.com

< Neuroaneurysm occlusion and delivery device and method of using same

< Combination treatment with t-PA variant and low molecular weight heparin

> Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1

> 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
~ 00230